Results 11 to 20 of about 31,337 (182)

The Mathematics of ‘Natural Beauty’ in the Architecture of Andrea Palladio and Le Corbusier: An Analysis of Colin Rowe’s Theory of Formal Complexity Using Fractal Dimensions

Fractal and Fractional, 2023
In a famous architectural discussion, Colin Rowe links the geometric properties of two sixteenth century villas by Andrea Palladio and two twentieth century villas by the architect Le Corbusier.
Michael J. Dawes, Michael J. Ostwald, Ju Hyun Lee   +2 more
doaj   +3 more sources

Colin Rowe, 1920–1999 [PDF]

Journal of Architectural Education, 2000
(2000). Colin Rowe, 1920–1999. Journal of Architectural Education: Vol. 53, No. 4, pp. 191-193.
exaly   +4 more sources

Calling Rowe: After-lives of Formalism in the Digital Age [PDF]

Footprint, 2018
Emmanuel Petit recently invoked the work of Colin Rowe to render a discussion of architectural precedent relevant for the digital age. Questioning Petit’s approach, this article explores the implications latent in this invocation.
Stylianos Giamarelos
doaj   +5 more sources

Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease. [PDF]

Alzheimers Dement
Abstract INTRODUCTION The cholinergic basal forebrain system, particularly the nucleus basalis of Meynert (Ch4), is selectively vulnerable to amyloid beta (Aβ) and tau in Alzheimer's disease (AD). Their interplay may be a critical driver of AD progression, but remains poorly understood. METHODS Data from 779 older individuals in the Australian Imaging,
Xia Y, Dean MW, Bourgeat P, Krishnadas N, Maruff P, Masters CL, Villemagne VL, Fripp J, Rowe CC, Doré V, Coulson EJ.   +10 more
europepmc   +2 more sources

Interpreting positive plasma Aβ42/40 results when amyloid PET is negative [PDF]

Alzheimers Dement
Abstract Background The agreement between plasma Aβ42/40 and Aβ‐PET is approximately 75%, with a large portion of discrepancies due to positive plasma with negative PET results. Questions remain about whether these reflect brain Aβ changes detectable in plasma before PET‐detectable.
Feizpour A, Bourgeat P, Dore V, Doecke J, Canovas R, Laws S, Porter T, Huang K, Fowler C, Weiner M, Morris J, Benzinger T, Schindler S, Bateman R, Ward L, Fripp J, Masters C, Villemagne V, Rowe C.   +18 more
europepmc   +3 more sources

Correlations of amyloid accumulation, brain atrophy and cognitive decline in emergent Alzheimer's disease [PDF]

Alzheimers Dement
Abstract Background Amyloid‐β (Aβ) deposition and dysfunction of the cholinergic basal forebrain (BF) system are early pathological features in Alzheimer's disease (AD). Given the continuous nature of Aβ accumulation, the extent of the corresponding changes in brain structure and cognitive performance at the emergent stage of AD, characterized by ...
Xia Y, Dore V, Fripp J, Bourgeat P, Lim Y, Laws S, Fowler C, Rowe C, Masters C, Coulson E, Maruff P.   +10 more
europepmc   +2 more sources

Harmonizing neuropsychological test data across prospective studies. [PDF]

Alzheimers Dement
Abstract INTRODUCTION Alzheimer's disease (AD) research relies on large datasets and advanced statistical models. However, individual population studies often lack sufficient sample size for conclusive results. Harmonizing cognitive test data across studies can address this gap, despite differences in testing protocols.
Shishegar R, Doecke JD, Lim YY, Bourgeat P, Dore V, Tallapragada B, Laws SM, Porter T, Burnham S, Feizpour A, Gillman A, Weiner M, Hassenstab J, Rowe CC, Villemagne VL, Masters CL, Fripp J, Sohrabi H, Maruff P, Alzheimer's Disease Neuroimaging Initiative, OASIS‐3, and the Australian Imaging Biomarkers and Lifestyle flagship study of ageing.   +21 more
europepmc   +2 more sources

Combining Lumipulse pTau217 and Aβ42 as confirmatory tests for Aβ pathology prior to DMT [PDF]

Alzheimers Dement
Abstract Background With the increasing number of countries approving disease‐modifying therapies (DMTs) for patients with either Mild Cognitive Impairment (MCI) or mild Alzheimer's disease (AD), it is vitally important to streamline treatment assessment processes. Blood‐based biomarkers (BBMs) have been suggested as rivals to cerebrospinal fluid (CSF)
Doecke J, Chenna A, Lo M, Badal Y, Yee B, Martone R, Petropoulos C, Fowler C, Laws S, Rainey‐Smith S, Martins R, Rowe C, Masters C, Winslow J.   +13 more
europepmc   +2 more sources

Sex, education and race/ethnicity have distinct effects on amyloid and tau‐PET status [PDF]

Alzheimers Dement
Abstract Background Sex, education and race/ethnicity are all associated with risk of Alzheimer's disease dementia. Here, we assess the effects of self‐reported sex, educational attainment and race/ethnicity on amyloid‐positivity, and tau‐PET‐positivity in 12,048 (7,394 cognitively unimpaired [CU], 2,177 MCI, and 2,477 dementia) individuals from 42 ...
Groot C, Coomans E, Rowe C, Dore V, Feizpour A, van de Giessen E, van der Flier W, Pijnenburg Y, Visser P, den Braber A, Pontecorvo M, Burnham S, Kennedy I, Lu M, Jagust W, Baker S, Harrison T, Gispert J, Shekari M, Minguillón C, Smith R, Mattsson‐Carlgren N, Palmqvist S, Strandberg O, Stomrud E, Brickman A, Luchsinger J, Manly J, Lao P, Kreisl W, Malpetti M, O'Brien J, Rowe J, Jäger E, Bischof G, Drzezga A, Xie F, Mao X, Guan Y, Garibotto V, Frisoni G, Peretti D, Schöll M, Skoog I, Kern S, Sperling R, Johnson K, Risacher S, Saykin A, Carrillo M, Dickerson B, Apostolova L, Rabinovici G, Barthel H, Rullmann M, Messerschmidt K, Vandenberghe R, Laere K, Spruyt L, Petersen R, Jack C, Franzmeier N, Brendel M, Gnörich J, Benzinger T, Lagarde J, Sarazin M, Bottlaender M, Villeneuve S, Poirier J, Seo S, Gu Y, Kim J, Mormino B, Young C, Vossler H, Rosa‐Neto P, Therriault J, Rahmouni N, Coath W, Cash D, Schott J, Hanseeuw B, Salman Y, Malotaux V, Jansen W, Joie R, Rosen H, Johnson S, Christian B, Betthauser T, Landau S, O'Bryant S, Hansson O, Ossenkoppele R.   +94 more
europepmc   +2 more sources

Heterogeneous tau patterns in atypical AD are explained by connectivity‐associated tau progression [PDF]

Alzheimers Dement
Abstract Background The link between regional tau load and clinical manifestation of Alzheimer's disease (AD) highlights the importance of characterizing spatial tau distribution. In typical (memory‐predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicenters. However, atypical (non‐amnestic‐
de Bruin H, Groot C, Alzheimer's Disease Neuroimaging Initiative (ADNI), Barthel H, Bischof G, Blazhenets G, Boellaard R, Boon B, Brendel M, Cash D, Coath W, Day G, Dickerson B, Doering E, Drzezga A, van Dyck C, van Eimeren T, van der Flier W, Fredericks C, Fryer T, van de Giessen E, Gordon B, Radford J, Grinberg L, Hansson O, Hobbs D, Höglinger G, Hönig M, Irwin D, Jones P, Josephs K, Katsumi Y, Joie R, Lee E, Levin J, Malpetti M, McGinnis S, Mecca A, Mohanty R, Nasrallah I, O'Brien J, O'Dell R, Palleis C, Perneczky R, Phillips J, Putcha D, Rabinovici G, Rahmouni N, Rosa‐Neto P, Rowe J, Rullmann M, Sabri O, Saur D, Schildan A, Schott J, Schroeter M, Seeley W, Servaes S, Sintini I, Smith R, Spina S, Stevenson J, Stomrud E, Strandberg O, Therriault J, Tideman P, Touroutoglou A, Trainer A, Visser D, Wekselman F, Weston P, Whitwell J, Wolk D, Yong K, Pijnenburg Y, Franzmeier N, Ossenkoppele R.   +76 more
europepmc   +2 more sources